Editorial Board About Us

Lower urinary tract symptoms

All articles from this key word are listed below.

Volume 11, Supplement 1 Review Articles

Efficacy of a-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms

Advances in the Pharmacologic Treatment of BPH

Claus G Roehrborn

Male lower urinary tract symptoms (LUTS) are one of the most common causes for a consultation with a health care provider, and one of the most common causes of male LUTS is benign prostatic hyperplasia (BPH). In recent decades, medical therapy has established itself as viable and cost effective for the majority of men. For the treatment of male LUTS in the United States, the 5 currently available α-adrenergic receptor blockers are alfuzosin, doxazosin, silodosin, terazosin, and tamsulosin. α-Blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They exhibit an early onset of efficacy (within less than 1 week) with regard to both symptoms and flow rate improvement, maintain such improvements in open-label and controlled trials for up to 5 years, and have been shown to prevent symptomatic progression.[Rev Urol. 2009;11(suppl 1):S1–S8 doi: 10.3909/riu11S1S0003]© 2009 MedReviews®, LLC

Benign prostatic hyperplasia Lower urinary tract symptoms Blockers

Volume 11, Supplement 1 Review Articles

Side Effects of a-Blocker Use: Retrograde Ejaculation

Advances in the Pharmacologic Treatment of BPH

Steven A Kaplan

There are currently 5 α-blockers that are approved by the US Food and Drug Administration to treat lower urinary tract symptoms (LUTS). The American Urological Association guidelines committee believes that all α-blockers are equally effective. However, α-blockers differ in their likelihood of causing abnormal ejaculation. This article discusses the effects on ejaculatory function, and specifically retrograde ejaculation, of the currently available α-blockers being used to treat men with LUTS due to benign prostatic hyperplasia.[Rev Urol. 2009;11(suppl 1):S14–S18 doi: 10.3909/riu11S1S0001]© 2009 MedReviews®, LLC

Benign prostatic hyperplasia Lower urinary tract symptoms Blockers

Volume 11, Supplement 1 Review Articles

Medical Management of Lower Urinary Tract Symptoms

Advances in the Pharmacologic Treatment of BPH

Eric E Laborde Kevin T McVary

Lower urinary tract symptoms (LUTS) are a common complaint among aging men and are often caused by benign prostatic hyperplasia (BPH). A number of medical treatments for LUTS/BPH exist, such as α-blockers, 5α-reductase inhibitors, anticholinergics, phosphodiesterase type 5 (PDE5) inhibitors, and combination therapies. Agonist binding of the α1A-adrenergic receptor (AR), causing prostatic smooth muscle contraction, has been attributed to cause some LUTS. Therefore, medical therapy has aimed to block the α1A-AR and improve LUTS. Determining which therapy to choose must take into account individual patient factors as well as cost and patient choice.[Rev Urol. 2009;11(suppl 1):S19–S25 doi: 10.3909/riu11S1S0004]© 2009 MedReviews®, LLC

Lower urinary tract symptoms Phosphodiesterase Combination therapy Blockers 5-reductase inhibitors Anticholinergics Benign prostatichyperplasia

Volume 11, Number 3 Meeting Reviews

New Insights in Pediatric Urology

Highlights From the American Academy of Pediatrics Section on Urology Meeting,October 10-13, 2008, Boston, MA[Rev Urol. 2009;11(3):166-168 doi: 10.3909/riu.0444]© 2009 MedReviews®, LLC

Lower urinary tract symptoms Vesicoureteral reflux Enuresis Undescended testis

Volume 11, Number 2 Meeting Reviews

Best of the 2009 AUA Annual Meeting

Highlights From the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL

Arie S Belldegrun Naoki Yoshimura B Shuch F Pouliot Dean G Assimos Ellen Shapiro Alan W Partin Michael B Chancellor Stacy Loeb J Curtis Nickel Claus G Roehrborn Michael K Brawer

Prostate cancer screening Obesity Benign prostatic hyperplasia Lower urinary tract symptoms Vesicoureteral reflux Nephrolithiasis Stress urinary incontinence Inflammation Silodosin Hormonal therapy Tumor markers TMPRSS2ERG 4-Kallikrein panel Botulinum toxin type A Male voiding dysfunction Benign prostatic specific antigen Roux-en-Y gastric bypass surgery Genitourinary pain index UPOINT clinical phenotype system Nephron-sparing surgery Watchful waiting Laparoscopy for adrenal cortical carcinoma Partial adrenalectomy Urethral trauma Pediatric urethral stricture Enteric urologic surgery

Volume 12, Number 4 Review Articles

State of the Art in Intravesical Therapy for Lower Urinary Tract Symptoms

State of the Art

Jonathan Kaufman Vikas Tyagi Michele Anthony Pradeep Tyagi Michael B Chancellor

Intravesical therapy is the routine first-line treatment for effectively delaying or preventing the recurrence of bladder cancer. This route of drug administration has also shown tremendous promise in the treatment of interstitial cystitis/painful bladder syndrome (IC/PBS) and potentially overactive bladder to justify investments for further improvements. This review takes a bird’s eye view into the current status of intravesical therapy, with emphasis on liposomal nanoparticles, in diseases associated with lower urinary tract symptoms (LUTS). Ongoing efforts to advance the field of intravesical drug delivery include development of sustained-release drug implants and efforts to improve delivery of biotechnological products including large protein acting as neurotoxins and small interfering RNAs.[Rev Urol. 2010;12(4):e181-e189 doi: 10.3909/riu0496]© 2010 MedReviews®, LLC

Lower urinary tract symptoms Interstitial cystitis Intravesical therapy Painful bladder syndrome

Volume 13, Number 1 Review Articles

Medical Treatment of Benign Prostatic Hyperplasia

Disease State Review

"Medical therapy for the treatment of benign prostatic hyperplasia (BPH) became an accepted standard of care in the 1990s following the reports of randomized, double-blind, placebo-controlled studies showing that finasteride, a 5-_ reductase inhibitor, and terazosin, an _-blocker, significantly improved lower urinary tract symptoms and increased peak urinary flow rates in men with BPH. This article reviews novel approaches to the pharmacological treatment of BPH. [Rev Urol. 2011;13(1):20-33 doi: 10.3909/riu0519]"

Benign prostatic hyperplasia Lower urinary tract symptoms Monotherapy

Volume 14, Number 3 Review Articles

Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

Treatment Update

Dean S Elterman Richard K Lee Alexis E Te Steven A Kaplan Bilal Chughtai

Many aging men will experience both erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), resulting in lower urinary tract symptoms (LUTS). Basic and clinical evidence suggests common pathogenic mechanisms underlying both LUTS and ED. Decreases in the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway with age result in decreased levels of intracellular cGMP and calcium, leading to diminished smooth muscle relaxation of the bladder and prostate and worsening LUTS. Phosphodiesterase type 5 inhibitors as monotherapy in combination with a-blockers have shown efficacy in treating both LUTS and ED. Tadalafil has recently been approved by the US Food and Drug Administration for the treatment of LUTS secondary to BPH, with or without concomitant ED. [Rev Urol. 2012;14(3/4):79-86 doi: 10.3909/riu0559] © 2013 MedReviews®, LLC

Benign prostatic hyperplasia Lower urinary tract symptoms Erectile dysfunction Phosphodiesterase inhibitors Tadalafil Sildenafil Vardenafil

Volume 16, Number 1 Case Review

Bladder Leiomyoma Presenting With LUTS and Coexisting Bladder and Uterine Leiomyomata: A Review of Two Cases

Sudhir Kumar Jain Raman Tanwar Aparajita Mitra

Mesenchymal tumors of the urinary bladder are a rare occurrence, the most common among them being leiomyoma of the bladder. These tumors commonly present with irritative urinary symptoms progressing gradually to obstructive symptoms as the size increases. We report on two patients who presented with lower urinary tract symptoms (LUTS). One of the patients also had concomitant bladder and uterine leiomyomata, which is the first such case to be reported in the literature. It is essential to differentiate leiomyoma from other common causes of LUTS. Cold cup biopsy has a significant false-negative rate and, in such cases, a wide local excision provides an optimal cure with excellent results. [Rev Urol. 2014;16(1):50-54 doi: 10.3909/riu0586] © 2014 MedReviews®, LLC

Lower urinary tract symptoms Bladder leiomyoma Uterine fibroid

Volume 17, Number 3 Review Articles

The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy

Management Update

Michael S Borofsky James E Lingeman Herbert Lepor Ojas Shah Ganesh Sivarajan

Lower urinary tract symptoms (LUTS) secondary to benign prostatic hypertrophy (BPH) are among the most common medical issues for aging men. Population-based studies suggest that 13.8% of men in their 40s and more than 40% of men over age 60 have BPH. When LUTS are refractory to medical therapy and bothersome enough to warrant surgical intervention, transurethral resection of the prostate and open simple prostatectomy have been the historical reference-standard procedures for decades. Both procedures are highly effective and offer durable improvements in urinary functional outcomes. However, they also have the potential for considerable perioperative complications and morbidity. In an effort to limit surgical morbidity, a variety of minimally invasive surgical techniques to treat BPH have been introduced. Herein we present a comprehensive, evidence-based review of the efficacy and safety profile of modern minimally invasive treatments for large-gland BPH. [Rev Urol. 2015;17(3):140-149 doi: 10.3909/riu0675] © 2015 MedReviews®, LLC

Lower urinary tract symptoms Robotic simple prostatectomy Benign prostatic hypertrophy GreenLight photovaporization Holmium laser enucleation of the prostate (HoLEP)